Placeholder Banner

BIO Comments on FDA's Revised Draft Guidance on Submission of Quality Metrics Data

March 27, 2017

BIO submitted comments on the Food and Drug Administration’s draft guidance, Submission of Quality Metrics Data.

BIO says it’s clear FDA has seriously considered the feedback on the 2015 Draft Guidance for Industry Request for Quality Metrics. In addition, BIO remains supportive of FDA’s effort to modernize regulatory oversight of drug quality and promotion of post-approval improvements. BIO provides additional suggestions on implementation, assessment, confidentiality of data, reporting for certain covered establishments, quality metrics, and more.

 

Download Full Comments Below
2017-3-27 BIO Comments On Revised Quality Metrics FINAL
Click the link below for full comments
Discover More
On November 9, BIO submitted comments on the FDA Draft Guidance, Drug-Drug Interaction Assessment for Therapeutic Proteins. In the comments, BIO thanks the FDA for the opportunity to submit comments but requests that the Guidance include a…
On August 6, BIO submitted comments on the NMPA Draft Technical Guideline on Clinical Trials of Cellular Immunotherapy Products. In the comments, BIO thanks NMPA for the opportunity to submit comments but argues for a more robust commenting period…
October 30, 2020 Re: Docket No. FDA–2020-D-1564: FDA Draft Guidance, Principles for Selecting, Developing, Modifying, and Adapting Patient-Reported Outcome Instruments for Use in Medical Device Evaluation. Dear Sir/Madam: The Biotechnology…